Leigh Perreault, MD
Endocrinology, Diabetes & Metabolism · Boulder, CONPI 1669562344
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,174,061 of the $1,657,614 with a category attached, or 70.8%. 15 manufacturers reported payments, led by Lilly USA, LLC at 29.9% of the total. Among endocrinology, diabetes & metabolism clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,583 payments — averaging $1047.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$496K
- Novo Nordisk$483K
- Boehringer Ingelheim$260K
- Sanofi-aventis U.S. LLC$122K
- AstraZeneca$75K
- Bayer$52K
- plus $169K from 9 others
What the payments were for
- Consulting fees$276,75717%
- Speaking & faculty fees$1,174,06171%
- Travel & lodging$177,00611%
- Food & beverage$29,7842%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 571 | $495,927 |
| Novo Nordisk | 380 | $483,498 |
| Boehringer Ingelheim | 292 | $260,492 |
| Sanofi-aventis U.S. LLC | 49 | $122,125 |
| AstraZeneca | 86 | $75,311 |
| Bayer | 58 | $51,585 |
| Merck | 38 | $45,268 |
| Boehringer Ingelheim International GmbH | 36 | $42,730 |
| Johnson & Johnson | 26 | $33,971 |
| Eli Lilly | 33 | $31,483 |
| Novo Nordisk AS | 9 | $11,610 |
| Ascendis Pharma Endocrinology Inc | 2 | $3,540 |
| Amarin Pharma, Inc. | 1 | $28 |
| Amryt Pharma Holdings Ltd | 1 | $27 |
| Mannkind Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,657,614 in reported general payments places this provider in the 95th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 105 | $147,950 |
| OzempicSemaglutide | 67 | $144,952 |
| MounjaroTirzepatide | 89 | $134,502 |
| TrulicityDulaglutide | 44 | $62,334 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $33,462 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $30,784 |
| NovologInsulin Aspart | 18 | $4,315 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $3,955 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 24 | $3,404 |
| SynthroidLevothyroxine Sodium | 11 | $757 |
| Pioglitazone Hcl | 35 | $729 |
| Levothyroxine Sodium | 39 | $311 |
| Metformin Hcl | 34 | $286 |
| Losartan Potassium | 27 | $239 |
| Rosuvastatin Calcium | 17 | $188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $495,927 | $196,836133 claims |
| Novo NordiskOzempic, Novolog | $483,498 | $149,26785 claims |
| Boehringer IngelheimJardiance | $260,492 | $147,950105 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
Other endocrinology, diabetes & metabolism in Boulder
- Vinaya KamathBoulder$1K
- Kimberly LernerBoulder$1K
- Satish GargAurora$347K
- Viralkumar ShahAurora$256K
- Neda RasouliAurora$188K
- Michelle CassaraArvada$141K
- Halis AkturkAurora$109K
- Irinel StanciuArvada$104K
- Robert EckelAurora$66K
- Marc Andre CornierAurora$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.